Mirati wins over a Chinese partner for KRAS hopeful, looking to tail Amgen's breakthrough win
In a gunshot heard across oncology, the FDA handed Amgen a breakthrough win for a first-of-its-kind KRAS inhibitor — once considered “undruggable” — late last week …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
